Amarantus BioScience to Present at Biotech Showcase 2013
SUNNYVALE, Calif., Dec. 27, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong will make a corporate presentation at Biotech Showcase 2013 on Wednesday January 9, 2013 at 9:00am PST at the Parc 55 Wyndham Hotel in San Francisco, CA. The corporate presentation at Biotech Showcase 2013 will be made the day after the presentation of Parkinson's neurorestoration animal data by CSO Dr. John Commissiong and concurrent scientific overview of the broader MANF opportunity by Dr. Joseph Rubinfeld, an Advisor to Amarantus. The Company will make the Biotech Showcase 2013 webcast link available on its website at www.amarantus.com several days before the event.
"The presentations scheduled the week of the healthcare industry's largest annual congregation of key decision makers in San Francisco will provide an ideal platform to introduce Amarantus to the broader investment community and biopharmaceutical executives," said Gerald E. Commissiong, President & CEO.
About Biotech Showcase™ 2013
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
The 2012 event showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. Now in its fifth year, Biotech Showcase 2013 is expected to feature presentations by close to 250 public and private companies and attract more than 1,500 attendees. The event will host a full program of topical plenary sessions and workshops. www.biotechshowcase.com
About Amarantus BioScience, Inc.
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.
Amarantus BioScience, Inc.
IR Sense, LLC
SOURCE Amarantus BioScience, Inc.